|
|
Article: NewCo News Biokine Gets $1.2M to Kick Off Phase I/II Trial with CXCR4 Drug.
- Article from:
- BIOWORLD Today
- Article date:
- March 18, 2009
- Author:
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Byline: Trista Morrison, Staff Writer
Biokine Therapeutics Ltd. received a $1.2 million research grant and initiated its first clinical trial with lead compound BKT140, a selective antagonist of the chemokine receptor CXCR4.
The Rehovot, Israel-based company is expected to announce both items on Wednesday.
The grant -- which was awarded by the Office of the Chief Scientist of the Ministry of Industry, Trade and Labor of Israel -- brings Biokine's fundraising total to slightly more than $5 million to date.
That total includes seed financing provided by the company's founders and the Weizmann Institute of Science incubator as well as ...